← Leaderboards
Mark J Federspiel
Mayo Clinic Coll Of Medicine, Rochester
$5,784,512
Attributed
$5,784,512
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $703.7K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,784,512 · 6
By mechanism
P30$2,787,166 · 3
R33$1,909,423 · 2
R01$1,087,923 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Lewis R Roberts$8,981,499
- Stephen J Russell$9,318,537
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusClinicTranslationsCancer TherapyBaseProgramsProductionGenesResearch PersonnelPre-ClinicalCellsUnited States National Institutes Of HealthTechnologyTumorMalignant NeoplasmsIn VitroFundingMemberViralPhase I Clinical TrialsRetroviridaeCollaborationsComprehensive Cancer CenterQuality Control
Grant awards (26)
Gene and Virus Therapy Shared Resource$173,579
P30 · FY2022 · CA · contact PI
Gene and Virus Therapy Shared Resource$173,455
P30 · FY2021 · CA · contact PI
Gene and Virus Therapy Shared Resource$175,897
P30 · FY2020 · CA · contact PI
Gene and Virus Therapy Shared Resource$169,849
P30 · FY2019 · CA · contact PI
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics$298,354
R33 · FY2017 · CA · contact PI
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics$76,654
R33 · FY2016 · CA · contact PI
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics$375,008
R33 · FY2015 · CA · contact PI
Validating Technology To Optimize Antibody Affinity For Targeting Therapeutics$375,008
R33 · FY2014 · CA · contact PI
Gene Virus$259,963
P30 · FY2013 · CA · contact PI
Gene Virus$252,399
P30 · FY2012 · CA · contact PI
Gene Virus$269,972
P30 · FY2011 · CA · contact PI
Gene Virus$286,834
P30 · FY2010 · CA · contact PI
Gene Virus$284,644
P30 · FY2009 · CA · contact PI
CORE--GENE & VIRAL THERAPY$210,051
P30 · FY2008 · CA · contact PI
Technology to Optimize scFvs for Targeting Therapeutics$254,302
R33 · FY2007 · CA · contact PI
Retrovirus Entry and Virus Evolution$242,261
R01 · FY2007 · AI · contact PI
CORE--GENE & VIRAL THERAPY$207,102
P30 · FY2007 · CA · contact PI
Technology to Optimize scFvs for Targeting Therapeutics$261,897
R33 · FY2006 · CA · contact PI
Retrovirus Entry and Virus Evolution$249,496
R01 · FY2006 · AI · contact PI
CORE--GENE & VIRAL THERAPY$111,921
P30 · FY2006 · CA · contact PI
Technology to Optimize scFvs for Targeting Therapeutics$268,200
R33 · FY2005 · CA
Retrovirus Entry and Virus Evolution$255,500
R01 · FY2005 · AI
CORE--GENE &VIRAL THERAPY$108,662
P30 · FY2005 · CA
Retrovirus Entry and Virus Evolution$255,500
R01 · FY2004 · AI
CORE--GENE &VIRAL THERAPY$102,838
P30 · FY2004 · CA
Retrovirus Entry and Virus Evolution$85,166
R01 · FY2003 · AI